

Global Journal of Health Science (GJHS)

Evaluation of Adherence to World Health Organization Guidelines on Clinical Management of Cryptococcal Meningitis among Health Care Providers in Selected Hospitals, Kisumu, Kenya

Robina Ogendo



Evaluation of Adherence to World Health Organization Guidelines on Clinical Management of Cryptococcal Meningitis among Health Care Providers in Selected Hospitals, Kisumu, Kenya



Robina Ogendo

Department of Nursing, University of Kabianga, Kenya

Article History

Received 3rd February 2024

Received in Revised Form 7th March 2025

Accepted 4th April 2025



How to cite in APA format:

Ogendo, R. (2025). Evaluation of Adherence to World Health Organization Guidelines on Clinical Management of Cryptococcal Meningitis among Health Care Providers in Selected Hospitals, Kisumu, Kenya. *Global Journal of Health Sciences*, 10(2), 16–27. <https://doi.org/10.47604/gjhs.3281>

Abstract

Purpose: Prevalence of Cryptococcal meningitis has risen and remained high over the last several decades in line with the HIV/ADS pandemic which has consequently led to the increase of Cryptococcal Meningitis associated mortality rates ranging from 17% to 100% in Africa. The aim of the present study was to assess the adherence to WHO guidelines on clinical management of CM in adults among HCP in JOOTRH and KCRH.

Methodology: This was a cross-sectional analytical study which was carried out in Kisumu County, Kenya. Sample size was obtained using Yamane (1967) formula. The sample calculation yielded a sample size of 119 respondents with a 97% response rate. Bivariate analysis was done using logistic regression from which chi square, odds ratios and the p- values were drawn

Findings: Findings from demographics showed that many were females (n=64, 55.2 %). Distribution of age bracket showed that many (n=74, 64.3%) were aged 30 years or below. From the results, 76% (n=88) reported using lumbar puncture with rapid CrAg assay while very few reported using lumbar puncture with rapid cerebral spinal fluid India ink test (3%, n=4) in diagnosing cryptococcal meningitis. Majority (90.5%, n=105) reported using amphotericin B deoxycholate + fluconazole as first line antifungal therapy. In management of hypokalemia, majority (93%, n=56) did not monitor potassium daily but all (100%, n=60) administered 1 liter of normal saline infused with 20 mEq of potassium chloride two hours prior to each infusion of amphotericin B. 93% (n=56) did not administer two of 250-mg tablets of magnesium trisilicate, or magnesium chloride 4 mEq twice/ day for supplementation of magnesium.

Unique Contribution to Theory, Practice and Policy: This study recommends that the County government of Kisumu in collaboration with the two hospital management teams, need to organize and provide periodic training opportunities for the health care providers on the WHO guidelines on management of Cryptococcal meningitis whose prevalence is high in this region, and consistently avail current recommended clinical guideline/protocols in all the clinical departments to ease reference, hence promote adherence. In addition, they should include the aspect of adherence to WHO guidelines on management of cryptococcal meningitis, as one of the yearly appraisal objectives and provide timely supportive supervision in order to promote and streamline optimal adherence.

Keywords: Cryptococcal Meningitis, Guidelines, Adherence, Health Care Providers

©2025 by the Authors. This Article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0>)

INTRODUCTION

Meningitis is an inflammatory disorder of the meninges, which are structures that cushion the spinal cord and brain to provide protection. Most patients with this infection at least develop fever, severe headache, and neck rigidity and associated altered level of consciousness (Ganiem, 2013).

According to WHO (2018), cryptococcal meningitis has a case fatality rate which has remained high ranging between 35%- 65%, in Sub-Saharan Africa, comparing with 20%-30% in most developed countries. This case fatality rate is escalated because this infection is the most prevalent opportunistic infection in people living with HIV/AIDS. With early diagnosis of Cryptococcal Meningitis(CM), consistence adherence to the basic principles of clinical guidelines by health care providers, and control of the underlying disease, this infection can successfully be managed in majority of patients (Perfect, *et al.*, 2010). Failure to adhere to clinical standards results into overtreatment or under treatment leading to a reduction of potential benefits with increased risks. On the other hand, adherence to standards assures provision of recommended care and also minimizes health care costs. In addition, there is a realization of quality of care when recommendations are followed than when they are not (Sidorenkov, *et al.*, 2011). According to Austad *et al.*, (2015), to improve quality, minimize variations in provision of health care and assist in setting priorities among HCP, clinical practice guidelines are developed. The gold standard recommended guidelines for management of cryptococcal meningitis in adults as per WHO (2018) include; early diagnosis, prevention, screening and treatment of CM, timing of ART in HIV infected patients, management and prevention of Amphotericin B deoxycholate toxicity, monitoring for and managing of increased intracranial pressure (ICP), monitoring treatment response and managing relapse. Oyella *et al.*, (2012) advocates for screening for CM in all patients newly diagnosed with HIV infection, living with HIV infection and have associated low CD4 counts of less than 50cells/mm³ for appropriate plan of action.

In addition, those individual patients with compromised immunity secondary to HIV infection and are malnourished with a very low body mass index (BMI) accompanied with clinical presentations of meningitis should equally be screened for CM for prompt management to promote desirable patient outcome. Abbas, *et al.*, (2016) points out a common diagnostic tool for CM to be India ink staining and culture of the yeast as the definitive test for diagnosis of cryptococcal meningitis. In addition, CSF, serum, or plasma CrAg should be offered for all patients thought to suffer from meningitis. On the other hand, the CrAg lateral flow assay remains a convenient diagnostic test in the point of care. According to Cox & Perfect *et al.*, (2018), the most effective therapeutic intervention for the patient with cryptococcal meningoencephalitis in the induction phase consists of amphotericin B plus flucytosine, in consolidation phase, fluconazole is administered and continued throughout the maintenance phase. In addition, throughout therapy, monitoring of patients for recurrence of clinical symptoms suggestive of increased intracranial pressure, relapse of infection as a result of non-adherence or drug resistance, adverse events following antifungal therapy, and IRIS secondary to antiretroviral therapy should not be overemphasized.

The WHO (2011) advises administration of a combination of Fluconazole and Flucytocine or high dose of stand-alone Fluconazole during the induction phase in the absence of Amphotericin B, then continue with 8 weeks of consolidation phase of oral Fluconazole and finally provide a maintenance phase of oral fluconazole. Sloan & Parris, (2014) states that HIV positive patients with asymptomatic cryptococcal must be initiated on ART promptly.

According to John & Pradeep, (2017) the fungicidal therapy goal in HIV co-infected patients with CM is to eradicate and control the infection in acute phase then continue with a longstanding fluconazole regimen to suppress the cryptococcal organism. In patients with cryptococcal infection without HIV comorbidity, the therapeutic goal may differ. Mdodo *et al.*, (2010), emphasizes on the recommended clinical standards for treatment of AIDS associated CM for sub-Saharan Africa as; induction phase of 1 mg/kg/day AmpB for two weeks, consolidation period of Fluconazole 800 mg for four weeks, Fluconazole 400mg or 200mg orally for eight weeks, followed by a maintenance phase Fluconazole 200 mg until CD4 counts were >200 cell/ μ L. Rothe *et al.*, (2013) noted significant baseline CNS complications and poor clinical outcomes with associated increased deaths from cryptococcal meningitis in HIV infected adults related to fluconazole monotherapy. With early diagnosis of CM, consistence adherence to the basic principles of clinical guidelines by health care providers, and control of the underlying disease, this infection can successfully be managed in majority of patients (Perfect, *et al.*, 2010). Failure to adhere to clinical standards results into overtreatment or under treatment leading to a reduction of potential benefits with increased risks. On the other hand, adherence to standards, assures provision of recommended care and also minimizes health care costs. In addition, there is a realization of quality of care when recommendations are followed than when they are not (Sidorenkov, *et al.*, 2011).

Problem Statement

Among people infected with HIV worldwide, the CM burden is estimated at 0.04% to 12% per year, resulting to 625000 deaths (Sogbanmu *et al.*, 2014). In the absence of treatment, HIV associated CM has 100% case fatality rate hence life threatening (Adeyemi & Ross, 2014). The clinical management strategies suitable for the control of cryptococcal meningitis in HIV infected patients by WHO 2018 include, early antiretroviral therapy (ART) initiation in HIV infected patients, early initiation of proper antifungal therapy followed by early and immediate referral for HIV care after diagnosis of cryptococcal disease. A South African study revealed inadequate observance to the recommended clinical strategies in the control of cryptococcal meningitis (Sogbanmu, *et al.*, 2014). Prevalence of HIV is unacceptably higher by 3.4 times in Kisumu than at the national level which is 19.9 %, this has resulted to escalated cases of HIV associated cryptococcal meningitis (Kenya HIV Estimates, 2015). Although the gold standard recommended CM control guidelines by WHO (2018) are in place, cryptococcal meningitis disease is the major reason for reported deaths amongst HIV infected patients in underdeveloped areas where Kisumu County in Kenya is included.

METHODOLOGY

The study was conducted in two referral public hospitals in Kisumu County and ethics approval was obtained from Masinde Muliro University of Science and Technology ethics board, National commission for science and technology and the Kisumu County commission.

Research Design

The study designs adopted for this study was cross-sectional analytical and applied a quantitative approach. Cross sectional analytical study design was ideal as the study was carried out in a limited geographical scope and hence it was logistically easier and simpler to conduct considering the limitations of this study. Therefore, the cross-sectional analytical design was deemed the best strategy to fulfill the objectives of this study.

Study Setting

The research was performed in the medical wards, outpatient departments and the patient support center (PSC) of Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) and Kisumu County Referral Hospital (KCRH) in September – December, 2019. JOOTRH is located in Kisumu county, Kisumu East constituency, Kondele ward. It is now the largest referral hospital in Western Kenya and serves more than 100 county and sub-county hospitals in the region. Its main mandate is to provide curative, preventive, promotive, diagnostic and rehabilitative services. It serves a catchment population of 83642 (JOOTRH Hospital Strategic Plan, 2016-2021). On the other hand, KCRH is the second largest public hospital in Kisumu County located in Kisumu city center, Kisumu East constituency, Railways ward. It serves the peripheral facilities and offers diagnostic curative, preventive, promotive, and rehabilitative services. The hospital refers its complicated cases to JOOTRH for further management.

Participants

Mugenda and Mugenda (2008) defined population as all elements (individuals, objects and events) that meet the sample criteria for inclusion in a study. The target population were the qualified health care providers offering care to adult patients suffering from CM in the medical wards, patient support center (PSC) and outpatient clinics in the two hospitals. Proportionate random sampling method was applied in the selection of the sample. This sampling method produces approximations of total population parameters with high accuracy, thereby guaranteeing a more representative sample obtained from a fairly homogeneous population. In addition, proportionate methods goal is to decrease standard error by affording slight control over variance (Barbie, 2004). In this study, the sample size was obtained using Yamane (1967) formula. This sampling method was suitable because the sample population was homogeneous and was less than 10,000. The sample size calculation yielded a sample of 119 respondents with a 97% response rate. A total of 60 observations was achieved during the study period. The inclusion criteria were all qualified health care providers employed in the medical units, outpatient clinics/casualty and the patient support center for at least three month. The exclusion criteria were all the qualified health care providers in the target population who did not consent to participate in the study.

Questionnaire

Questionnaires were selected as data collection instruments. Kothari, (2007), clarifies that self-administered questionnaires are the only way to prompt peoples' attitudes, beliefs, opinions and values. The researcher applied questionnaires in the collection of primary data to examine the demographics of the health care providers. In addition, an observational check list was used to evaluate the adherence to WHO guidelines among health care providers (HCP). An instruction for selecting the responses was provided in all the sections. The questionnaire consisted of closed ended questions. The observation check list was scored according to individual HCP's performance during observation. To increase the validity of the instruments, the questionnaire was evaluated by experts. Then based on the feedback the final questionnaire was prepared for pre-test. The pretest study was conducted in Ahero County hospital. The reliability of the scale of the questionnaire was found to be: Internal consistency = (Cronbach's $\alpha = 0.701$).

Data Analysis

Data analysis was done using the statistical program for social sciences (SPSS) version 25. Descriptive and inferential statistics were used to analyze data. Descriptive analysis of data was done using the mean, frequencies and percentages. In this study association between the study variables was assessed by a two-tailed probability value of $p < 0.05$ for significance. Visual inspection of the data illustrated that missing data appeared to be missing at random. Univariate analysis was used to describe the distribution of each of the variables in the study objective, appropriate descriptive analysis was used to generate frequency distributions, tables and other illustrations used to analyze community knowledge. Bivariate analysis was done using logistic regression from which the chi square, odds ratios and the p- values were drawn.

RESULTS

The research targeted a sample size of 119 respondents out of which 116 completed and returned the questionnaires, making a total response rate of 97%. According to Mugenda and Mugenda (2003) a response rate of 50 percent is adequate, a response rate of 60 percent is good, and a response rate of 70 percent is very good. Therefore, the 97 percent response rate reported for this study formed an acceptable basis for drawing conclusions. The study sought to obtain information on the respondents' background characteristics based on the gender, job title, experience, age bracket and unit currently working. The summary of their responses is given in Table 1.

Table 1: Demographic Background Characteristics of Respondents

		N	%
Gender	Male	52	44.8
	Female	64	55.2
Age groups	30 years and below	74	64.3
	31-40 years	24	20.9
	41-50 years	9	7.8
	51 years and above	8	7.0
Job title	medical consultant	5	4.3
	medical officer	14	12.1
	nursing officer	78	67.2
	clinical officer	19	16.4
Experience categories	5 years and below	75	64.7
	6-10 years	17	14.7
	11-20 years	12	10.3
	20 years and above	12	10.3
Unit of work	male medical ward	52	44.8
	female medical ward	37	31.9
	patient support center	15	13.0
	outpatient clinics	12	10.3

With regard to their gender profiles, many were females ($n=64$, 55.2 %). This implied that majority of health workers in public hospital in the study area are female as opposed to males. Distribution of age bracket showed that many ($n=74$, 64.3%) were aged 30 years or below. Results on their job titles revealed that majority ($n=78$, 67.2%) were nursing officers while

only a few (n=5, 4.3%) were medical consultants. A Greater part of the respondents had experience of 5 years or below (n=75, 64.7%).

Adherence to WHO Guidelines on Clinical Management of Cryptococcal Meningitis

The information was obtained via observation checklists. Firstly, with regards to methods of diagnosis of cryptococcal meningitis, it was observed that 100 % (n=60) did history taking of the patient and physical examination. An analysis of feedback is shown on Table 2 below.

Table 2: Adherence to WHO Guidelines on Clinical Management of Cryptococcal Meningitis

	Yes		No	
	n	%	n	%
History taking	60	100.0	0	0.0
Physical examination	60	100.0	0	0.0
Diagnostic tests;				
Lumber puncture with measurements of CSF fluid opening pressure	0	0.0	60	100.0
Lumber puncture with rapid CSF CrAg assay	60	100.0	0	0.0
Lumber puncture with CSF India ink test	40	66.7	20	33.3
Rapid serum/whole blood CrAg assay	60	100.0	0	0.0
Induction phase of treatment				
Two weeks amphotericin B 1mg/kg/day + fluconazole 1200mg/day	60	100.0	0	0.0
Fluconazole 800mg daily for 8 weeks following induction phase	44	73.3	16	26.7
Preventing, monitoring and managing of amphotericin B toxicity				
Serum potassium:				
Initial Serum potassium	60	100.0	0	0.0
Serum potassium 2-3 times/week in the second week of amphotericin B administration	20	33.3	40	66.7
Hypokalemia				
Daily serum potassium measurement	4	6.7	56	93.3
20 mEq of potassium chloride infused in 1 liter of normal saline over two hours before each dose of amphotericin B	60	100.0	0	0.0
8-mEq potassium chloride 1-2 tablets orally twice daily	0	0.0	60	100.0
8-mEq tablet may be added twice/ day during the second week	4	6.7	56	93.3
Supplement magnesium 2 of 250-mg tablets of magnesium trisilicate twice / day, or magnesium chloride 4 mEq twice/ day	4	6.7	56	93.3
Serum creatinine				
Initial serum creatine measurement	60	100.0	0	0.0
Serum creatine 2-3 times weekly in the second week of amphotericin B therapy	16	26.7	44	73.3
Timing of ART in HIV positive patients				
Withhold ART 4-6 weeks from the initiation of antifungal drugs	56	93.3	4	6.7
Give blood transfusion in severe Amphotericin B related anemia	32	53.3	28	46.7
Monitoring for raised intracranial pressure				
Have an initial lumbar puncture	60	100.0	0	0.0
Measurement of CSF opening pressure	0	0.0	60	100.
Perform repeat lumbar puncture with measurement of CSF opening pressure	0	0.0	60	100.0
Management of raised intracranial pressure				
Therapeutic lumbar puncture	16	26.7	44	73.3
Persistent raised intracranial pressure				
Perform lumbar puncture if possible, every day with measurements of CSF opening to evaluate progress	0	0.0	60	100.0
Monitoring treatment response				
Performed every day in the period of induction therapy	60	100.0	0	0.0

With regards to diagnostic tests, none (0%, n=0) did LP with measurement of CSF fluid opening pressure, all (100%, n=60) did the rapid serum/whole blood CrAg assay and LP with rapid CSF CrAg assay, majority (67%, n=40) did lumbar puncture with CSF India ink test while did the rapid serum. In the induction phase of treatment all (100%, n=60) gave two weeks amphotericin B 1mg/kg/day + fluconazole 1200mg/day while a majority (73%, n=44) of them gave Fluconazole 800mg daily for 8 weeks following induction phase. With regards to monitoring, preventing and managing of amphotericin B toxicity, all (100%, n=60) did serum potassium baseline, majority (67%, n=40) did not perform serum potassium 2-3 times every week in the second week of amphotericin B drug therapy.

In management of hypokalemia, majority (93%, n=56) did not monitor potassium daily but all (100%, n=60) administered 1 liter of normal saline infused with 20 mEq of potassium chloride beyond two hours prior to each infusion of amphotericin B. 93% (n=56) did not administer two of 250-mg tablets of magnesium trisilicate, or magnesium chloride 4 mEq twice/ day for supplementation of magnesium. In monitoring of serum creatine, all (100%, n=60) measured initial serum creatine levels but 73% (n=44) did not measure 2-3 times/ week during the second week of amphotericin B drug therapy. In timing of ART, in HIV co- infected patients, 93% (n=56) withheld HAART for 4-6 weeks following the initiation of antifungal regimen. In monitoring for raised intracranial pressure, all (100%, n=60) did not measure CSF opening pressure and also did not carry out a repeat lumbar puncture with measurement of CSF opening pressure to for monitoring of patient progress.

In management of raised intracranial pressure all (100%, n=60) did not do repeat daily therapeutic lumbar puncture (with measurements of CSF opening pressure where available. With regards to monitoring treatment response, all (100%, n=60) assessed patient response to treatment every day during the first two weeks of induction treatment. The observation checklist had a total of twenty-five items. Each response was given a mark based on the level on the dichotomous scale with the anchors being No=0 to Yes=1 and vice versa for items that were reverse coded. Scale scores were computed by adding responses to the seven items causing a minimum possible score of 0 and a maximum of 25.

Respondents who scored below the mean score of 20.6 were classified as not adhering to WHO guidelines and those that scored above the mean score were classified as adhering to WHO guidelines.

- Adhering to WHO guidelines (above mean score of 20.6)
- Not adhering to WHO guidelines (Below mean score of 20.6)

From the results, many of the health care workers were adhering to WHO guidelines (n=37, 61%), while 39% (n=23) did not adhere to WHO guidelines (Figure 2)




Figure 1: Adherence to who Guidelines on Clinical Management of Cryptococcal Meningitis

Bivariate Analysis of Socio-Demographic Characteristics Associated With Adherence to WHO Guidelines

A Bivariate logistic regression was done to evaluate the relationship amongst adherence and socio demographic characteristics. Nurses were 40% less likely to adhere compared to clinical officers (OR: 0.6; 95% CI: 0.4 – 0.9; $p=0.01$). Males were 1.2 times more likely to adhere compared to females (OR: 1.2; 95% CI: 0.8 – 1.9; $p=0.3$). This is shown in the Table 6 below

Table 3: Socio Demographic Characteristics Associated With Adherence to WHO Guidelines

		Adhere		Don't Adhere		Overall OR	95% CI	p value
		n	%	n	%			
Job Titles	Nurses	14	45.1	18	54.9	0.6	0.4 – 0.9	0.01
	Medical officers	3	33.3	7	66.7	0.7	0.2 – 2.7	0.7
	Clinical officers	7	40.9	11	59.1	*	*	*
Gender	Females	18	46.4	21	53.6	1.2	0.8 – 1.9	0.3
	Males	4	16.7	17	83.3			

* Reference category

Discussion

The objective of the present study was to assess the adherence of WHO guidelines on clinical management of cryptococcal meningitis in adults among health care providers in Kisumu County. $p=0.97$). This study results show that, 61% ($n=37$) of the health care providers were adhering to WHO guidelines, the results further reveal that nurses were 40% less likely to adhere to the WHO recommended guidelines on management of CM compared to clinical officers (OR: 0.6; 95% CI: 0.4 – 0.9; $p=0.01$), in addition, males were 1.2 times more likely to adhere compared to females (OR: 1.2; 95% CI: 0.8 – 1.9; $p=0.3$). The study also realized 100% ($n=60$) history taking and physical examination of patients by the clinicians, this is consistent with the WHO 2018 guidelines which recommends that earlier diagnosis, and prompt treatment of cryptococcal meningitis and its complications, is required to lessen the incidence and related high death rate in resource limited settings. All the HCP (100%, $n=60$) performed rapid

serum/whole blood assay and lumbar puncture with rapid CSF CrAG assay while 67%, (n=40) of HCP performed lumbar puncture with CSF India ink test to diagnose CM. This is in line with the WHO 2018 guidelines and a study done by Oyella et al., 2012 which encourages clinicians to be vigilant in diagnosis of cryptococcal disease in vulnerable patients who present with meningeal irritation, neck pain, a low BMI, and a recent HIV diagnosis before ART initiation for suitable intervention. It is established from this study that all the health care providers (100%, n=60) gave two weeks amphotericin B 1mg/kg/day + fluconazole 1200mg/day in the induction phase of treatment while a majority (73%, n=44) of them gave Fluconazole 800mg daily for 8 weeks following induction phase. This finding indicates that the HCP in the study area instituted appropriate therapy in the induction phase according to the WHO guidelines 2018 on clinical management of cryptococcal meningitis and a study done by Govender et al, 2013.

Although this study realizes that all the HCP (100%, n=60) did administer 20 mEq of potassium chloride infused in 1 liter of normal saline over two hours before each infusion of amphotericin B, all HCP (n=60) never monitored potassium daily and only 67% (n=40) checked the serum potassium levels 2-3 times weekly. This practice contradicts the recommended WHO guidelines, 2018. This finding proves that the monitoring of AMP B toxicity was not sufficiently performed in the study area hence increasing the risk for mortality from preventable AMP B toxicity. In addition, 93% (n=56) did not administer Magnesium to counteract AMP B complications. This outcome is commensurate to those of a comparable research done in South Africa by Sogbanmu et al., 2014 which revealed that preload and potassium supplementation were not done during the management of patients with CM. It is noted from the study that all the health care providers (100%, n=60) measured serum creatine at baseline but a large number of the HCP (73% n=44) did not measure 2-3 times weekly as stipulated in the WHO recommended guidelines. Majority of the HCP (93% n=56) of HCP did timing of ART, in HIV patients, through withholding it 4-6 weeks following antifungal treatment hence prevention of IRIS as a result of ART. This latter finding is in line with a study carried out by Cox & Perfect, 2018 on clinical management of CM. All the HCP (100%, n=60) neither measured CSF opening pressure nor performed any subsequent lumbar puncture with measurement of CSF opening pressure as recommended by WHO 2018 to monitor patient progress in regard to raised ICP. In addition, all the HCP (100%, n=60) did not perform repeat daily therapeutic lumbar puncture and CSF opening pressure measurement as a means of managing raised ICP. These results agree with a study carried out in 2014 by Adeyemi & Ross which noted that previous studies had shown critical disparities in clinicians' compliance to recommendations on management of CM. However, all the HCP (100%, n=60) assessed the patients for response to treatment on a daily basis during the induction phase of regimen, this practice is line with the WHO 2018 recommended guidelines.

CONCLUSION AND RECOMMENDATIONS

The study concludes that critical effective aspects in the WHO recommended guidelines in the management of CM such as measurement of CSF opening pressure, daily observation of serum potassium levels, monitoring of serum creatinine 2-3 times weekly and daily repeat of therapeutic lumbar puncture in management of raised intracranial pressure, were not done in this study during the study period. This finding can be associated with the increased CM mortality rate in the study area. The County government of Kisumu in collaboration with the two hospital management teams in the study area, need to organize and provide periodic training opportunities for the HCP on the WHO guidelines on management of CM whose

prevalence is high in this region, and consistently avail current recommended clinical guideline protocols in all the clinical departments to ease reference, hence promote adherence. In addition, they should include the aspect of adherence to WHO guidelines on management of cryptococcal meningitis, as one of the yearly appraisal objectives and provide timely supportive supervision in order to promote and streamline optimal adherence.

REFERENCES

- Adeyemi, B.O., & Ross, A. (2014). *Management of cryptococcal meningitis in a district hospital in Kwazulu-Natal: A clinical Audit*. Afr j prm Health care fam Med. 2014; 6(1), Art.//672, 6 pages.
- Babbie, E. (2004). *The practice of social research* (10th Ed); Thomson Belmont CA: Wadsworth Publishing Company.
- Ganiem, A.R., Indrati, A.R., Wisaksana, R., Meijerink, H., & Van der Ven A. (2014). Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia. *J Int AIDS Soc* 17: 18821.
- Govender, N.P, Meintjes, G., Bicanic, T., Dawood, H., Harrison, T.S., Jarvis, J.N. (2013). Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update by the Southern African HIV Clinicians Society. *S Afr J HIV Med.*; 14(2):76±86.
- Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, March 2018. Geneva: World Health Organization. License: CC BY-NC-SA 3.0 IGO.
- Kothari, C. R. (2007). *Research Methodology: Methods and Techniques*. New Delhi: New Age International Publishers
- Mdodo, R., Moser, S.A., Jaoko, W., Baddley, J., Pappas, P., Kempf, M.C. (2011). *Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya*. Mycoses; 54(5): e438–42.
- Mugenda & Mugenda (2003), *Research Methods: Quantitative and Qualitative Approaches*
- Oyella (2012): Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV infected adults in Uganda: a cross-sectional study. *Journal of the International AIDS Society*; 15:15.
- Perfect, J.R., Dismukes, W.E, Dromer, F., Goldman, D.L., Graybill, J.R., Hamill, R.J. (2010). *Clinical practice guidelines for the management of cryptococcal disease*: update by the infectious diseases society of America. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.; 50(3):291–322.
- Rothe, C., Sloan, D.J., Goodson, P., Chikafa, J., & Mukaka, M, (2013). *A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi*. PLoS ONE 8(6): e67311. doi: 10.1371/journal.pone.0067311.
- Sawadogo, S., Makumbi, B., Purfield, A., Ndjaveva, C., Mutandi, G., & Maher, A. (2016). Estimated Prevalence of Cryptococcus Antigenemia (CrAg) among HIV-Infected Adults with Advanced Immunosuppression in Namibia Justifies Routine Screening and Preemptive Treatment. PLoS ONE 11(10): e0161830. doi: 10.1371/journal.pone.0161830.
- Sidorenkov, G., Haaijer-Ruskamp, F.M, de Zeeuw, D., & Denig P. (2011). A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of Adequacy and Timeliness. PLoS ONE 6(9): e24278. doi: 10.1371/journal.pone.0024278.

- Sloan, D.J, &Parris, V. (2014). *Cryptococcal meningitis: Epidemiology and therapeutic options*. Clin Epidemiol 6: 169-182.
- World Health Organization (2011). *Rapid Advice- Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children*. Geneva: World Health Organization.
- Yamane, T. (1967): *Statistics: An Introductory Analysis*, 2nd Ed., New York: Harper and Row.